Of note, the phenomenon of new lesions in light of PSMA-directed RLT remains a matter of debate, as recently stated in the EANM consensus statement concerning the response assessment criteria in prostate cancer [18]. This evidence concerns the gene FOLH1 and prostate carcinoma.